Wikipedia
Vaniprevir
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4a protease inhibitor, developed by Merck & Co., which is currently in clinical testing.
In Japan, it was approved for treating hepatitis C in 2014.